Expression of complement inhibitor protein CD59 in human neuronal and glial cell lines treated with HIV-1 gp41 peptides

J Neurovirol. 2000 Feb;6(1):51-60. doi: 10.3109/13550280009006382.

Abstract

In attempts to elucidate the pathogenic mechanisms involved in neurodegeneration in AIDS patients with cognitive deficits, the possible effect of HIV-1 transmembrane envelope protein gp41 on expression of the membrane inhibitor of complement mediated cytolysis (CD59) was assessed in human neuronal (SK-N-SH) and astroglial (T98G) cell lines. Western blotting analyses demonstrated that an immunodominant (ID, aa 598-613) gp41 peptide as well as the recombinant gp41 protein encompassing this domain markedly reduced CD59 level in a dose dependent manner whereas p24 and control peptide had little effect. RT-PCR showed that ID peptide also elicited a reduction in the expressed CD59 mRNA level. This gp41 peptide apparently down-regulated phorbol 12,13-dibutyrate induced elevation of CD59 at the protein and mRNA levels in a manner similar to that conferred by protein kinase C inhibitor, H-7 or staurosporine in SK-N-SH. Interestingly, proinflammatory cytokines such as IL-1beta or IFN-gamma as well as LPS greatly decreased CD59 in SK-N-SH and to a lesser extent in T98G whereas TNF-alpha did not significantly alter it. In contrast, antioxidants and anti-inflammatory agents enhanced CD59 expression reversing gp41 peptide mediated inhibitory effect in SK-N-SH. Our data suggest that high level of gp41 or its metabolites as well as impaired protein kinase response, chronic inflammation or antioxidant depletion within HIV-1 infected brains may be associated with a diminished expression of CD59 which would render neuronal cells to susceptible to indirect bystander lysis in the presence of autologous complement.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / pharmacology
  • CD59 Antigens / biosynthesis*
  • CD59 Antigens / genetics
  • Carcinogens / pharmacology
  • Cell Line
  • Complement Inactivator Proteins / pharmacology*
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology
  • HIV Envelope Protein gp41 / immunology
  • HIV Envelope Protein gp41 / pharmacology*
  • Humans
  • Immunodominant Epitopes / immunology
  • Immunodominant Epitopes / pharmacology
  • Lipopolysaccharides / pharmacology
  • Neuroglia / cytology
  • Neuroglia / drug effects
  • Neuroglia / metabolism*
  • Neurons / cytology
  • Neurons / drug effects
  • Neurons / metabolism*
  • Peptide Fragments / immunology
  • Peptide Fragments / pharmacology
  • Phorbol 12,13-Dibutyrate / pharmacology
  • Protein Kinase C / antagonists & inhibitors
  • Protein Kinase C / drug effects
  • RNA, Messenger / metabolism
  • Staurosporine / pharmacology

Substances

  • CD59 Antigens
  • Carcinogens
  • Complement Inactivator Proteins
  • Enzyme Inhibitors
  • HIV Envelope Protein gp41
  • Immunodominant Epitopes
  • Lipopolysaccharides
  • Peptide Fragments
  • RNA, Messenger
  • Phorbol 12,13-Dibutyrate
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
  • Protein Kinase C
  • Staurosporine